AI Governance for Healthcare and Life Sciences.
Clinical staff, research teams, and operations are sending patient data, trial documentation, and sponsor-confidential material into ChatGPT, Copilot, Azure OpenAI, and internal AI tools. The gateway between those users and the model is where HIPAA, 21 CFR Part 11, and sponsor obligations need to be applied, because the content control plane the LLM provider offers stops at the model boundary and does not extend to the customer policy.
DeepInspect runs inline in front of the AI provider. PHI, clinical identifiers, and sponsor-restricted data are detected and transformed before the payload leaves the customer environment. Every decision is written to a tamper-evident forensic record with the policy version, the actor identity, and the original and transformed payloads preserved. The same configuration applies to interactive chat, retrieval-augmented applications, and autonomous agent workflows.
The risk surface in healthcare AI
PHI inside prompt payloads
Staff paste patient identifiers, free-text clinical notes, imaging metadata, and ICD codes into AI tools. The LLM provider keeps the payload long enough to serve the response and, under most enterprise agreements, longer for abuse detection. Once that payload leaves the customer boundary, the HIPAA Business Associate Agreement is the only remaining control, and the BAA covers retention, not the act of disclosure.
Audit evidence that auditors actually accept
FDA, EMA, and sponsor auditors ask the same question of AI usage that they ask of any regulated system: who accessed what data, when, under which policy, and what decision did the system produce. Most enterprises are unable to answer because the AI interaction log either does not exist or sits inside the LLM provider in a form the auditor cannot retrieve.
Provider content filters are not customer policy
Model providers apply safety filters to their own models. The HIPAA BAA, the sponsor data handling clause, and the institutional data classification scheme are customer artifacts. The model has no view of any of them, so the enforcement has to live at the gateway in front of the model.
Role-blind responses
A research coordinator and a principal investigator send the same prompt and the model returns the same content. Real governance requires that the same prompt produces different transformations based on the authenticated role, because the underlying data access policy already says so.
How DeepInspect applies controls
PHI detection and transformation
Deterministic detectors match the eighteen HIPAA Safe Harbor identifiers, common clinical free-text patterns, and diagnosis codes. Each match is redacted, tokenized, or blocked according to the configured action for the user role in effect. Tokenization keeps a reversible mapping inside the customer environment for downstream traceability while the upstream model sees only opaque tokens.
Identity-aware policy
Role identity is supplied by the customer IdP at request time. The gateway evaluates the per-role action map and applies the matching transformation. A principal investigator can receive tokenized identifiers for traceability while a junior analyst sees fully redacted payloads on the same policy. The action map is part of the policy version, so role changes are captured in the audit trail.
Evidence-grade forensic record
Every interaction writes a signed record containing the actor identity, the policy version, the rule evaluation path, the original payload, the transformed payload, and the upstream response. The signature anchors integrity. The record set is queryable by auditors against a read-only projection, and the audit path leaves its own trace so the enterprise sees exactly what the auditor retrieved.
Prompt injection and adversarial input handling
Adversarial inputs attempting to override instructions, extract trial protocols, or pivot an agent into restricted systems are scored against the configured detectors and blocked or routed to escalation according to policy. The score, the input, and the action are preserved in the forensic record.
Tool and agent allowlists
Autonomous agents in clinical workflows reach EHR APIs, trial management systems, and research repositories. The gateway enforces allowlists and blocklists on the tools an agent invokes and the data sources it reads. An agent that attempts to call a system outside its allowlist is stopped at the gateway with a record of the attempt.
Forensic deep analysis
Patterns across the forensic store surface anomalous access, repeated near-miss policy hits, and the kind of slow exfiltration that single-event monitoring misses. The analysis runs against the customer projection and produces queryable findings that map back to the source interactions.
Regulatory mapping
HIPAA and HITECH
PHI detection and transformation apply Safe Harbor handling at the AI layer. The signed audit trail supports the Security Rule 45 CFR 164.312(b) audit controls and 164.312(c) integrity requirements. Identity-aware access decisions cover 164.308(a)(4) information access management. Breach analytics over the forensic store support 164.402 breach assessment with the original payload preserved for the limited-data-set determination.
21 CFR Part 11
Cryptographically signed, time-stamped, attributable records of every AI interaction meet the electronic records requirements that Part 11 places on regulated clinical and manufacturing systems. The record set is exportable in the formats sponsor and FDA auditors expect.
ICH GCP and sponsor agreements
Sponsor-specific handling rules for trial protocols and subject data are encoded as per-role and per-route action maps. The policy version that applied to each interaction is preserved alongside the decision, which produces the contemporaneous record that sponsor inspections rely on.
EU AI Act
Clinical decision support and patient-facing AI fall inside the high-risk category. Policy versioning produces the change-control trail relevant to Article 17. The forensic record covers Article 12 record-keeping. Inline enforcement with fail-closed default behavior addresses Article 9 risk management. Identity-based restrictions apply Article 13 transparency to the actors a given rule concerns.
The scale of the gap
of healthcare organizations reported confirmed or suspected AI agent security incidents in the past year, the highest of any sector surveyed. The cross-industry average is 88%.
of organizations report that their entire AI agent fleet went live with full security and IT approval. The remainder is operating outside the standard review pipeline that already governs other production systems.
of builders cite the absence of auditability and logging as a top concern. Only 7.7% audit agent activity daily, which leaves most enterprises without the contemporaneous record that HIPAA and 21 CFR Part 11 require.
of teams treat AI agents as identity-bearing entities. The remainder authenticate agents with shared API keys or hardcoded credentials, which makes per-agent attribution and revocation impossible.
is the HIPAA Tier 4 willful-neglect maximum per violation category per year as of 2026. An uncontested finding turns on whether the covered entity can produce contemporaneous evidence that policy was applied.
Deployment
The gateway runs self-hosted in the customer VPC or on-premises. SaaS and hybrid deployments are available for organizations with different sovereignty requirements. PHI, the forensic store, and the transaction object store stay inside the customer boundary in every configuration.
DeepInspect sits inline between users, agents, and the AI provider. It works with OpenAI, Azure OpenAI, Anthropic, Bedrock, and internal models without requiring a model migration. Existing IdP, SIEM, and DLP investments stay in place. Production cutover typically lands inside two weeks for a defined application scope.
Policy on every AI interaction, enforced before data leaves the boundary.